

Full Paper

Direct Synthesis of a PDE 4 inhibitor by using Pd-Cu-Catalyzed C-H/C-Br Coupling of Benzoxazole with A Heteroaryl Bromide

Kiichi Kuroda, Shinjiro Tsuyumine, and Tomohiro Kodama

Org. Process Res. Dev., **Just Accepted Manuscript** • DOI: 10.1021/acs.oprd.6b00106 • Publication Date (Web): 10 May 2016Downloaded from <http://pubs.acs.org> on May 11, 2016

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.




1
2
3
4
5
6
7 **Direct Synthesis of a PDE 4 inhibitor by using**
8
9
10
11 **Pd-Cu-Catalyzed C-H/C-Br Coupling of**
12
13
14
15 **Benzoxazole with A Heteroaryl Bromide**
16
17
18
19

20
21 Kiichi Kuroda ^{†*}, Shinjiro Tsuyumine [†], Tomohiro Kodama [#]
22
23

24 [†]Process Chemistry Research and Development Laboratories, Technology Research &
25
26 Development Division, Sumitomo Dainippon Pharma Co., Ltd., 3-1-98 Kasugade-naka,
27
28 Konohana-ku, Osaka 554-0022, Japan
29
30
31

32 [#]DSP Cancer Institute, Sumitomo Dainippon Pharma Co., Ltd., 3-1-98 Kasugade-naka,
33
34
35 Konohana-ku, Osaka 554-0022, Japan
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table of Contents Graphic



1
2
3 **ABSTRACT** : A short and practical synthetic route of a PDE4 inhibitor (**1**) was established by
4 using Pd-Cu-catalyzed C-H/C-Br coupling of benzoxazole with a heteroaryl bromide. The
5
6 combination of Pd(OAc)₂-Cu(OTf)₂-PPh₃ was found to be effective for this key step.
7
8

9
10 Furthermore, telescoping methods were adopted to improve the yield and manufacturing time,
11
12 and two-step synthesis of **1** was accomplished in 71% overall yield.
13

14
15 Keywords: C-H/C-Br Coupling, C-H activation, benzoxazole, telescoping
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION:

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and dementia. Although Donepezil, Rivastigmine, Galanthamine, and Memantine are marketed as Alzheimer-type dementia, all of these compounds are used as symptomatic therapy and have not high satisfaction with treatment. Therefore, there are strong unmet medical needs in the development of AD therapy. **1** is PDE4 inhibitor and expected to improve memory impairment. In addition to the mechanism of action, **1** enhances BDNF signal transduction and induces NXF, a brain specific transcription factor, in the presence of low concentrations of BDNF. NXF induction is expected to lead to nerve regeneration and neuroprotective efficacy.




Figure 1. Chemical structure of **1**.

In this article, we would like to describe two synthetic methods of **1** developed for scale up. The First-generation synthesis was based on the medicinal chemistry route and successfully scaled up to produce 14 kg of active pharmaceutical ingredient (API) for early clinical trials. The Second-generation synthesis was devised that enables direct coupling of benzoxazole with a heteroaryl bromide, and confirmed by 300 g synthesis for scale up feasibility.


RESULTS AND DISCUSSION

First-generation synthesis: The initial medicinal chemistry route to **1** is shown in Scheme 1.¹

This route was capable for preparation of the small amounts of API needed for early toxicology studies, but it was not suitable for large-scale production due to the following issues: (i) the operational problem such as evaporation to dryness to obtain **4**, (ii) the use of possibly carcinogenic solvent 1,4-dioxane and a mutagenic 2-aminophenol, and (iii) the requirement for high temperature (240-250 °C)² and chromatographic purification for the synthesis of **7**.


This first-generation synthesis was applied to 14 kg campaign for early clinical trial without a problem accompanying scale-up.

Scheme 2. First-Generation Synthesis.



Second-generation synthesis: After the manufacture by the first-generation route, we examined more efficient synthetic route of **1** for future material supply. In order to reduce the number of manufacturing steps, we planned to synthesize the API skelton **7**, by direct coupling of benzoxazole with an aryl bromide **8** (Scheme 3). The advantage of this method is not only to shorten a number of manufacturing steps, but also to avoid using 2-aminophenol, which is known to be mutagenic.

Scheme 3. New approach for the synthesis of 7 by C-H/C-Br coupling



Heterobiaryl compounds are very important motifs in biologically active natural products and pharmaceuticals.³ These moieties has been synthesized by cross coupling of aryl-metal compounds with aryl halides (C-M/C-X coupling, M = metal).⁴ On the other hand, recent advances in the metal mediated direct C-H arylations of aryl compounds with aryl halides (C-H/C-X coupling) provide an efficient and ideal access to the target molecules because it can avoid the need to prepare stoichiometric amounts of aryl-metal reagent.⁵ Although the direct C-H arylations of arylazole with aryl halides have also been extensively studied to date, Miura and co-workers made a breakthrough in this area in 1998 by finding the catalyst system of Pd(OAc)₂/PPh₃/Cs₂CO₃ that is effective for the arylation of azole including (benzo)thiazoles

1
2
3 and (benz)oxazoles.^{6,7} It was noted that the reaction was significantly accelerated by the
4
5 addition of CuI (Scheme 4).
6
7
8
9
10

11
12 **Scheme 4. Arylation of azole reported by Miura and co-workers**
13
14





Table 1. Effects of the addition of copper salts



Entry	CuX(I)	Yield(%) ^a	Entry	CuX(II)	Yield(%) ^a
1	None	73	6	Cu(OAc) ₂	77
2	CuI	29	7	CuO	84
3	CuBr	39	8	CuBr ₂	86
4	CuCl	25	9	Cu(OTf) ₂	87
5 ^b	CuOTf	87	10	Cu(OTf) ₂	N.D. ^c

^aReaction yields were quantified by HPLC.

^b(CuOTf)₂•toluene complex was used.

^cThe reaction was carried out in the absence of Pd(OAc)₂.

Firstly, we applied the Miura's conditions to the coupling reaction of **8**⁸ with benzoxazole in the absence of a copper salt, and obtained the desired product **7** in 73% yield (Table 1, Entry 1). The addition of CuI was not effective for this reaction and the yield was lowered to 29% (Entry 2). Next, the effects of the other copper salts were examined (Entries 3-9). When CuBr or CuCl was used, the yields of **7** were low while the reaction was significantly accelerated by the addition of CuOTf, and the yield of **7** increased up to 87% (Entries 3-5). The yield by addition of Cu(OAc)₂ was slightly improved compared to the no copper salt conditions (Entry 6). On the other hand, the reaction with copper (II) salts such as CuO, CuBr₂ and Cu(OTf)₂ afforded **7** in high yields as in the case in CuOTf (Entries 7-9). These results indicate that the higher Lewis acidities of copper salts increase the reactivity, probably due to the activation of benzoxazole.

1
2
3 When Cu(OTf)₂ was used without Pd(OAc)₂, **7** was not formed (Entry 10)^{9,10}. In view of
4 reactivity, cost and availability, Cu(OTf)₂ was selected as additive. To the best of our
5 knowledge, this is the first example of the combination of Pd(OAc)₂ with Cu(OTf)₂ for C-H
6 arylations of arylazole.¹¹
7
8
9
10
11
12

13
14 In addition to above results, the solvent could be changed from NMP to toluene which was
15 used for later crystallization. The amount of Pd(OAc)₂ could be reduced to 5 mol%.
16
17
18

19
20 Although the effects of various ligands were examined next (Table 2), PPh₃ gave the best
21 result (Entry 1). This reaction did not proceed without ligand (Entry 2), and the other ligands
22 were not effective except for P^tBu (Entries 3-8)¹². As a result, readily available PPh₃ was
23 chosen a ligand.
24
25
26
27
28
29

30 Since the conditions of copper salt and ligand were identified, the molar ratio of PPh₃/ Pd in
31 coupling reaction was examined. It was found that the formation of unknown impurities was
32 most suppressed in the case of the ratio of PPh₃/Pd 2.5 without depressing reactivity. Then, the
33 reaction yield increased up to 94% under optimized conditions at 10 g scale.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Table 2. Effects of the ligands^a

Entry	Ligand	Time (h)	Residual ratio of 8 (LC area%) ^b
1	PPh ₃	6	<1
2	none	4	97
3	P(<i>o</i> -Tol) ₃	5	95
4	P ^t Bu ₃	8	<1
5	cataCXium [®] A	5	70
6	XPhos type	5	42
7	dppf	5	22
8 ^c	PEPPI-IPr	6	67


^aThe reaction was carried out by using Pd(OAc)₂ (5 mol%), Cu(OTf)₂ (20mol%), ligand (15 mol%), and Cs₂CO₃ (2.0 equiv.) in toluene at 100°C.

^bResidual ratio of **8** is **8** / (**8** + **7**)

^cThe reaction was carried out in the absence of Pd(OAc)₂, Cu(OTf)₂ and PPh₃.

cataCXium[®] A

XPhos type




PEPPI - IPr

Lastly, the efficient telescoping synthesis of **11** was also studied (Scheme 5). The initial approach to **11** required the isolation of intermediate **10** to remove triethylamine hydrochloride. It could be omitted by switching the base from triethylamine to potassium carbonate which was easily removed by filtration, and then the solution of **10** was directly used in the next step. In the hydrogenation of the nitro group of **10**, the use of platinum, sulfide, on carbon instead of palladium on carbon controlled the produce of a debromo compound completely. Only THF was used as a solvent in the telescoping method of **11** from **9**.

1
2
3 In addition, the telescoping was also incorporated into the coupling reaction and salt formation.
4
5 For this purpose, it was need to skip of isolation of **8** and **7**. When toluene/THF was used instead
6
7 of methanol, **8** could be extracted into the organic layer. After evaporation of THF, the solution
8
9 of **8** was used in the coupling reaction. After the work up of coupling reaction, **7** was treated with
10
11 fumaric acid and **1** was directly crystallized in a manner similar to the first-generation method.
12
13 Therefore, crude-**1** was synthesized in two-step from **9**. We demonstrated this second-generation
14
15 route in multi-hundred grams scale manufacturing. In the demonstration, 330 g of **11** was
16
17 synthesized from **9** in 71% over yield.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Scheme 5. Second-Generation Synthesis.



CONCLUSION

We have successfully developed two scalable synthetic methods of a PDE4 inhibitor **1**. Although first-generation synthesis based on the medicinal chemistry route was developed for early clinical trial use, the construction of a benzoxazole unit was not efficient and a mutagenic 2-aminophenol was used. In order to solve these problems, direct C-H arylation of benzoxazole was introduced to second-generation synthesis. It was found that the combination of $Pd(OAc)_2$ - $Cu(OTf)_2$ - PPh_3 is effective for C-H/C-Br coupling of benzoxazole with heteroaryl bromide. Furthermore, telescoping methods were adopted to improve the overall yield and operational efficiency, and two-step synthesis of **1** was accomplished in 71% over yield.

EXPERIMENTAL SECTION

General. ^1H and ^{13}C NMR spectra were recorded on a Bruker Ultrashield 400 Plus spectrometer at 400 and 100.6 MHz, respectively. Chemical shifts (δ) are given in parts per million, and tetramethylsilane was used as the internal standard for spectra obtained in DMSO-*d*6 and D₂O. Mass spectra were recorded on JEOL JMS-T100GC “AccuTOF GC” mass spectrometer with EI resource. HPLC was performed on a Agilent 1100 system; XBridge C18 column (4.6 mm i.d. \times 100 mm, 5 μ m); eluent: (a) 0.01 mol/L phosphate buffer (pH 6.8), (b) MeOH ; flow rate = 1.0 mL/min, Temperature: 40°C, UV detection at 220 nm, Gradient: (b/a) 10/90 (0 min) – 70/30 (0–30 min) – 70/30 (30–35 min) – 25/75 (35.1 min) – 10/90 (35.1–40 min). The purity listed is determined by area %. Metal analysis was performed using ICP-MS analysis (PerkinElmer ELAN DRC II). All reactions were carried out under nitrogen or argon atmosphere unless otherwise mentioned. Reagents and solvents were used as obtained from commercial suppliers without further purification.

First-Generation Synthesis (Scheme 2).

3-nitro-4-((tetrahydro-2H-pyran-4-yl)amino)benzoic acid (3). To the solution of 4-fluoro-3-nitrobenzoic acid (15.97 kg, 86.27 mol) in water (95.8 kg) was added triethylamine (21.82 kg, 215.68 mol) and 4-aminotetrahydro-2H-pyran (9.60 kg, 94.90 mol) at 65–72°C. The reaction mixture was stirred at 70°C for 7 h and then allowed to cool to 47°C. Acetic acid (12.95 kg, 215.68 mol) was added to the mixture at 47–52°C and the resulting slurry was stirred at 50°C for 0.5 h. After cooling to 25°C over 2 h, the slurry was filtered. The wet cake was washed with water (24.0 kg) and isopropyl alcohol (24.0 kg), and dried at 50 °C under vacuum to a constant

1
2
3 weight to give **3** (21.82 kg, 94.9%) as a yellow solid. Spectral data are consistent with those of
4
5 the literature.¹
6
7

8
9 ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.91 (br, 1H), 8.61 (d, *J* = 2.1 Hz, 1H), 8.21 (d, *J* = 7.7 Hz,
10
11 1H), 7.96 (d, *J* = 9.3, 2.1 Hz, 1H), 7.28 (d, *J* = 9.3 Hz, 1H), 3.46 (dt, *J* = 11.5, 2.1 Hz, 3H), 1.95
12
13 (dd, *J* = 2.4, 2.0 Hz, 2H), 1.67–1.58 (m, 2H).
14
15

16
17 ¹³C NMR (100 MHz, DMSO-*d*₆): δ 165.81, 146.15, 136.04, 130.49, 128.53, 117.35, 114.96,
18
19 65.56, 48.29, 32.03.
20
21

23 **2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-benzimidazole-5-carboxylic acid hydrochloride**

24
25 **(5)**. To the solution of **3** (21.75 kg, 81.69 mol) in MeOH (108.8 kg) and THF (217.5 kg) was
26
27 added 10% Pd/C (50% wet), and the mixture was stirred under hydrogen atmosphere (0.02 MPa)
28
29 at 26 °C for 2 h. Acetic anhydride (9.17 kg, 89.86 mol) was added, and the mixture was stirred
30
31 at 25–27 °C for 2 h. The mixture was filtered and washed with MeOH (10.88 kg). Aqueous HCl
32
33 (35%, 8.51 kg, 81.69 mol) was added, and the mixture was stirred at 40 °C for 4 h. The mixture
34
35 was filtered and washed two times with MeOH (32.63 kg × 2), and dried at 50 °C under vacuum
36
37 to a constant weight to give **5** (20.66 kg, 85.3%) as a yellow solid. Spectral data are consistent
38
39 with those of the literature.¹
40
41
42
43

44
45 ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.27 (d, *J* = 1.3 Hz, 1H), 8.16 (d, *J* = 8.8 Hz, 1H), 8.05 (d, *J*
46
47 = 8.8, 1.3 Hz, 1H), 4.86 (m, 1H), 4.06 (dd, *J* = 11.4, 4.2 Hz, 2H), 3.56 (t, *J* = 11.4, 2H), 2.94 (s,
48
49 3H), 2.42 (m, 2H), 1.99 (dd, *J* = 12.4, 2.6 Hz, 2H).
50
51

52
53 ¹³C NMR (100 MHz, DMSO-*d*₆): δ 166.49, 153.61, 133.32, 131.59, 127.56, 125.69, 115.83,
54
55 114.13, 66.13, 54.35, 30.00, 12.89.
56
57
58
59
60

1
2
3
4
5
6
7 **N-(2-hydroxyphenyl)-2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-benzoimidazole-5-**
8
9 **carboxamide (6).** To the solution of **5** (18.07 kg, 60.89 mol) in toluene (306.0 kg) and DMF
10 (8.87 kg) was added SOCl₂ (14.48 kg, 121.71 mol) at 75 °C. The reaction mixture was stirred at
11 75 °C for 7 h and then allowed to cool to 45°C. Toluene (108.0 kg × 2) was added to the mixture
12 and concentrated below 50 °C until the amount of distillate was 108.0 kg. The mixture was
13 cooling to 25 °C and the solution of 2-aminophenol (7.28 kg, 66.71 mol) in pyridine (10.57 kg,
14 133.62 mol) and NMP (90.1 kg) was added to the mixture, and was stirred at 27°C for 24 h.
15 Aqueous NaOH (24%, 22.26kg, 133.56 mol) was added to the mixture at 27–31 °C over 1h and
16 warmed up to 50°C. The water (180.0 kg) was added to the mixture at 51–53 °C over 1 h, and
17 the slurry was stirred at 50 °C for 1 h and was cooling to 25 °C over 1.5 h. After stirring at 25 °C
18 for 19 h, the slurry was filtered. The wet cake was washed with the mixture of NMP (9.00 kg)
19 and water (18.0 kg), and acetone (27.0 kg × 2), and dried at 48 °C under vacuum to a constant
20 weight to give **6** (19.78 kg, 92.5%) as a gray solid. Spectral data are consistent with those of the
21 literature.¹
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40
41 ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.76 (s, 1H), 9.54 (s, 1H), 8.20 (d, *J* = 1.4 Hz, 1H), 7.82 (dd,
42 *J* = 8.6, 7.2 Hz, 1H), 7.77 (d, *J* = 8.6 Hz, 1H), 7.71 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.06–7.01 (m, 1H),
43 6.93 (dd, *J* = 8.0, 1.4 Hz, 1H), 6.84 (td, *J* = 7.6, 1.4 Hz, 1H), 4.67–4.60 (m, 1H), 4.05 (dd, *J* = 7.6,
44 11.3, 4.3 Hz, 2H), 3.57 (dd, *J* = 11.3, 10 Hz, 2H), 2.65 (s, 3H), 2.45–2.35 (m, 2H), 1.88–1.84 (m,
45 2H).
46
47
48
49
50
51

52
53 ¹³C NMR (100 MHz, DMSO-*d*₆): δ 165.73, 153.52, 149.07, 142.45, 135.97, 127.22, 126.28,
54 125.40, 123.76, 121.20, 119.08, 118.12, 116.16, 111.33, 66.51, 52.60, 30.68, 14.65.
55
56
57
58
59
60

2-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-benzimidazol-5-yl]-1,3-benzoxazole

hemifumarate (1). To the solution of **6** (16.50 kg, 46.96 mol) in NMP (49.4 kg) and Toluene (25.1 kg) and DMF was added methanesulfonic acid (22.56 kg, 234.78 mol) at 23–56 °C. The mixture was heated to 125–129 °C and stirred for 8h under azeotropic dehydration. The mixture was cooled to 25°C, and toluene (256.0 kg) and aqueous NaOH (24%, 46.96 kg, 281.76 mol) was added. The aqueous layer was removed and the organic layer was washed two times with 20% aqueous NaCl (65.8 kg × 2). The organic layer was concentrated under reduced pressure bellow 50 °C to distill off 78.8 kg. Residue was adjusted to ca. 231.0 kg with additional toluene (1.2 kg) and heated to 69°C. Fumaric acid (0.16 kg, 1.41 mol) in NMP (1.7 kg) and seed crystal (17g) was added and stirred for 0.5 h. Additional fumaric acid (3.11 kg, 26.76 mol) in NMP (31.3 kg) was added dropwise over 0.5 h at 69°C and stirred for 0.5 h. Heptane (100.4 kg) was added dropwise over 0.5 h and stirred for 0.5h. The slurry was cooled to -1 °C over 11 h and filtered. The wet cake was washed two times with acetone (16.5 kg × 2), and dried at 48 °C under vacuum to a constant weight to give crude-**1** (15.36 kg, 83.6%, HPLC area 99.9%) as a pale brown solid.

The solution of crude-**16** (15.14 kg, 38.68 mol) in EtOH (230.6 kg) and water (57.6 kg) was filtered at 78 °C, and washed with the mixture of EtOH (12.13 kg) and water (3.03 kg). Filtrate was concentrated bellow 80 °C to distill off 91.3 kg and water (106.1 kg) was added. After stirring at 75–82°C for 1 h, the solution was cooled to 65°C and seed crystal (15g) was added and stirred at 60–62°C for 1 h. Water (197.2 kg) was added dropwise over 1 h at 58–50°C and stirred for 0.5 h. The slurry was cooled to 3 °C over 6.5 h and filtered. The wet cake was washed two times with acetone (15.2 kg × 2), and dried at 48 °C under vacuum to a constant weight to give **1** (14.1 kg, 93.1% , HPLC area >99.9%) as a pale brown solid. Spectral data are consistent

1
2
3 with those of the literature.¹
4

5 ¹H NMR (400 MHz, DMSO-*d*₆): δ 13.1 (br, 1H), 8.33 (d, *J* = 1.5 Hz, 1H), 8.06 (dd, *J* = 5.1,
6 1.6 Hz, 1H), 7.89 (d, *J* = 0.8 Hz, 1H), 7.82–7.76 (m, 2H), 7.43–7.38 (m, 2H), 6.64 (s, 1H),
7 4.71–4.62 (m, 1H), 4.06 (dd, *J* = 11.4, 4.3 Hz, 2H), 3.58 (dd, *J* = 11.7, 11.4 Hz, 2H), 2.67 (s, 3H),
8 2.47–2.36 (m, 2H), 1.90–1.86 (m, 2H).
9

10 ¹³C NMR (100 MHz, DMSO-*d*₆): δ 165.92, 163.26, 153.94, 150.20, 142.94, 141.75, 136.21,
11 133.93, 124.94, 124.67, 120.89, 119.40, 117.70, 112.44, 110.72, 66.50, 52.67, 30.70, 14.62.
12
13
14

15 16 17 18 19 20 21 22 23 24 25 **Second-Generation Synthesis (Scheme 5).** 26

27
28 **5-bromo-2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-benzimidazole hydrochloride (11).** The
29 reaction of 4-bromo-1-fluoro-2-nitrobenzene (**9**) with 4-aminotetrahydro-2H-pyran and
30 hydrogenation process of **10** was carried out in two batches at the same scale. To the solution of
31 K₂CO₃ (109.3 g, 0.79 mol) and 4-aminotetrahydro-2H-pyran (73.3 g, 0.73 mol) in THF (507.5
32 kg) was added **9** (145.0 g, 0.66 mol) in THF (73.0 g) at 63–66 °C over 0.5 h. After stirring under
33 reflux for 5h, the mixture cooled to room temperature, and THF (290.0 g) and 3% Pt-S/C (14.5
34 g) were added. The mixture was stirred under hydrogen atmosphere at 25 °C for 5 h and THF
35 (290.0 g) was added. The mixture was filtered and washed two times with THF (290.0 g × 2).
36 After filtrates (two batches) were combined into one batch, THF (870.0 g) was added at room
37 temperature and heated to 40 °C. Acetic anhydride (67.29 g, 0.66 mol) was added dropwise over
38 0.5 h and seed crystal (1.5g) was added and stirred at 42°C for 20 min. Additional acetic
39 anhydride (134.6 g, 1.32 mol) was added dropwise over 1 h and stirred for 3.5 h. Aqueous HCl
40 (35%, 164.1 g, 1.58 mol) was added dropwise over 0.5 h at 40°C and the mixture was stirred for
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 5 h. After cooling to 0 °C, the mixture was filtered and washed two times with acetone (435.0 g
4
5 × 2), and dried at 40 °C under vacuum to a constant weight to give **11** (401.3 g, 91.8%) as a
6
7
8 white solid.
9

10
11 ¹H NMR (400 MHz, D₂O): δ 7.84 (d, *J* = 1.8 Hz, 1H), 7.82 (d, *J* = 9.0 Hz, 1H), 7.60 (dd, *J* =
12
13 9.0, 1.8 Hz, 1H), 4.86–4.80 (m, 1H), 4.14 (dd, *J* = 11.8, 4.7 Hz, 2H), 3.65 (td, *J* = 12.1, 1.9 Hz,
14
15 2H), 2.55–2.45 (m, 2H), 2.01–1.96 (m, 2H).
16
17

18
19 ¹³C NMR (100 MHz, D₂O): δ 151.60, 131.49, 129.54, 128.59, 118.54, 117.00, 115.46, 66.71,
20
21 54.69, 29.68, 11.97.
22
23

24
25 HRMS (EI) exact mass calcd for C₁₃H₁₅BrN₂O (M – HCl) 294.0368, found: 294.03711.
26
27

28
29 **2-[2-methyl-1-(tetrahydro-2*H*-pyran-4-yl)-1*H*-benzimidazol-5-yl]-1,3-benzoxazole**
30
31 **hemifumarate (1)**. Spectral data are consistent with those of the first generation synthesis. To
32
33 the solution of **11** (359.5 g, 1.08 mol) in Toluene (3200 g), THF (3200 g), and water (640.0 g)
34
35 was added aqueous NaOH (27%, 176.7 g, 1.19 mol) and heated to 37 °C. The aqueous layer was
36
37 removed and the organic layer was washed with water (960.0 g). After removing the aqueous
38
39 layer, the organic layer was concentrated under reduced pressure below 50 °C to distill off 4302
40
41 g. Toluene (4554 g) was added and the organic layer was concentrated to distill off 4942 g.
42
43 Additional toluene (4604 g) was added and the organic layer was concentrated to distill off 4877
44
45 g. After analyzing water and THF content in toluene solution (173 ppm and 0.01%, respectively),
46
47 the solution was adjusted to 2528 g with additional toluene (388.0 g). To the solution of **8** was
48
49 added PPh₃ (35.5 g, 0.136 mol), Cs₂CO₃ (706.4 g, 2.168 mol), Cu(OTf)₂ (706.4 g, 0.217 mol),
50
51 Pd(OAc)₂ (12.2 g, 0.054 mol), benzoxazole (258.3 g, 2.168 mol) and toluene (32.0 g) under
52
53 nitrogen flow. Additional nitrogen substitution was performed with vacuum deairing (three
54
55
56
57
58
59
60

1
2
3 times). After analyzing oxygen concentration (0.1%), the mixture was heated to 100 °C and
4
5 stirred for 1 h. After additional heating to 110 °C, the mixture was stirred for 2 h. Toluene (4800
6
7 g) was added, and the mixture was filtered at 80 °C and washed two times with toluene (480.0 g
8
9 × 2). Activated carbon (32.0 g) was added and stirred for 1 h. ISOLUTE[®] Si-Thiol (32.0 g) was
10
11 added as metal scavenger and stirred for 3 h. The mixture was filtered at 80 °C and washed two
12
13 times with toluene (160.0 g × 2). The filtrate was concentrated to distill off 2129 g was adjusted
14
15 to 6080 g with additional toluene (187.0 g). PPh₃ (14.2 g, 0.054 mol) was added at 80 °C and
16
17 stirred for 0.5 h. Fumaric acid (3.8 g, 0.033 mol) in NMP (32.0 g) and seed crystal (0.35 g) was
18
19 added and stirred for 0.5 h. Additional fumaric acid (71.7 g, 0.618 mol) in NMP (608 g) was
20
21 added dropwise over 1.5 h at 80 °C and stirred for 0.5 h. Heptane (1440 g) was added dropwise
22
23 over 0.5 h and stirred for 0.5h. The slurry was cooled to 0 °C over 5 h and stirring was performed
24
25 for another 14 h. The slurry was filtered and the wet cake was washed two times with acetone
26
27 (640.0 g × 2), and dried at 50 °C under vacuum to a constant weight to give crude-**1** (329.8 g,
28
29 77.7%, HPLC area 99.5%) as a pale brown solid. The content of Pd and Cu was 18 and 0.8 ppm,
30
31 respectively.
32
33
34
35
36
37
38
39

40 To the solution of crude-**16** (20.0 g, 51.00 mmol) in EtOH (304.0 g) and water (76.0 g) was
41
42 added ISOLUTE[®] Si-Thiol (0.2 g) at 78 °C. After stirring 2 h, the mixture was filtered and
43
44 washed with the mixture of Ethanol (16.0 g) and water (4.0 g). Filtrate was concentrated under
45
46 reduced pressure to distill off 120.0 g and water (140.0 g) was added. After heating to 78 °C, the
47
48 solution was cooled to 59°C and seed crystal (2.0 g) was added and stirred for 1.5 h. Water
49
50 (260.0 g) was added dropwise over 1 h at 59 °C and cooled to 2 °C over 4 h. Stirring was
51
52 performed for another 15 h and filtered. The wet cake was washed two times with acetone (20.0
53
54 g × 2), and dried at 40 °C under vacuum to a constant weight to give **1** (19.1 kg, 95.5% , HPLC
55
56
57
58
59
60

1
2
3 area 99.9%) as a white to pale yellow solid. The content of Pd and Cu was 0.3 and 0.1 ppm,
4
5 respectively.
6
7
8
9
10

11 12 **ASSOCIATED CONTENT**

13
14 Supporting Information

15
16
17
18 NMR spectra for compounds (PDF)
19
20
21
22
23

24 25 **AUTHOR INFORMATION**

26
27
28 *Corresponding Author

29
30
31 kiichi-kuroda@ds-pharma.co.jp
32

33
34 Notes

35
36 The authors declare no competing financial interest.
37
38
39

40 41 **ACKNOWLEDGMENT**

42
43 We thank Dr. Yuji Fujiwara for proofreading of the manuscript.
44
45
46
47
48

49 50 **REFERENCE**

51
52
53 (1) (a) Ishikawa, J.; Saito, K.; Ohe, N.; Kobayashi, K. PCT int. Appl. WO2010/137349 A1. (b)

54
55 Patent pending

56
57 (2) For an example of synthesis of benzoxazole by using B(OH)₃, see: Kauffman, J. M.; Moyna,
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

G. J. Heterocyclic. Chem. **2002**, *39*, 981.

(3) For review, see: a) Yeh, V. S. C. *Tetrahedron* **2004**, *60*, 11995. b) Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. *Angew. Chem. Int. Ed.* **2005**, *44*, 4442. c) Carey, J. S.; Laffan, D.; Thomson, C.; Williams, M. T.; *Org. Biomol. Chem.* **2006**, *4*, 2337.

(4) Metal-Catalyzed Cross-Coupling Reactions, 2nd ed.; de Meijere A., Diederich, F.; Eds.; Wiley-VCH, Weinheim, 2004. (b) Cross-Coupling Reactions: A Practical Guide; Miyaura, N.; Ed.; Topics in Current Chemistry, Vol. 219, Springer, Berlin, 2002.

(5) For recent review, see: a) Miura, M.; Satoh, T.; Hirano, K. *Bull. Chem. Soc. Jpn.* **2014**, *87*, 751. b) Yamamoto, T.; Muto, K.; Komiyama, M.; Canivet, J.; Yamagushi, J.; Itami, K. *Chem. Eur. J.* **2011**, *17*, 10113. c) Rossi, R.; Belina, F.; Lessi, M.; Manzini, C.; *Adv. Synth. Catal.* **2014**, *356*, 17. d) Roger, J.; Gottumukkala, A. L.; Doucet, H. *ChemCatChem* **2010**, *2*, 20.

(6) Pivsa-Art, S.; Satoh, T.; Kawamura, Y.; Miura, M.; Nomura, M. *Bull. Chem. Soc. Jpn.* **1998**, *71*, 467.

(7) The first C-H arylations of (benz)oxazole was reported by reported by Ohta and coworkers, see: Aoyagi, Y.; Inoue, A.; Koizumi, I.; Hashimoto, R.; Tokunaga, K.; Gohma, K.; Komatsu, J.; Sekine, K.; Miyafuji, A.; Kunoh, J.; Honma, R.; Akita, Y.; Ohta, A. *Heterocycles* **1992**, *33*, 257.

(8) The compound **8** was prepared from commercially available **9** in a manner similar to a first-generation approach.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (9) For examples of Cu catalyzed C-H arylation of azoles, see: a) Kim, D.; Yoo, K.; Kim, S. E.; Cho, H. J.; Lee, J.; Kim, Y.; Kim, M. *J. Org. Chem.* **2015**, *80*, 3670. b) Nishino, M.; Hirano, K.; Satoh, T.; Miura, M. *Angew. Chem. Int. Ed.* **2013**, *52*, 4457. c) Zhang, W.; Zeng, Q.; Zhang, X.; Tian, Y.; Yue, Y.; Guo, Y.; Wang, Z. *J. Org. Chem.* **2011**, *76*, 4741.
- (10) For examples of Cu(OTf)₂ catalyzed synthesis of benzoxazole from benzanilides, see: a) Ueda, S.; Nagasawa, H. *Angew. Chem. Int. Ed.* **2008**, *47*, 6411. b) Ueda, S.; Nagasawa, H. *J. Org. Chem.* **2009**, *74*, 4272.
- (11) For examples of Pd-Cu catalytic system for C-H arylation of heteroarenes, see: a) Huang, J.; Chan, J.; Chen, Y.; Borths, C. J.; Baucom, K. D.; Larsen, R. D.; Faul, M. M. *J. Am. Chem. Soc.* **2010**, *132*, 3674. b) Yan, X.-M.; Mao, X.-R.; Huang, Z.-Z. *Heterocycles* **2011**, *83*, 1371. c) Alagille, D.; Baldwin, R. M.; Tamagnan, G. D. *Tetrahedron Lett.* **2005**, *46*, 1349.
- (12) For an example of NHC-Pd complex catalyzed C-H arylation of (benz)oxazole, see: Shen, X.-B.; Zhang, Y.; Chen, W.-X.; Xio, Z.-K.; Hu, T.-T.; Shao, L.-X. *Org. Lett.* **2014**, *16*, 1984.